Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top 10 Correlated ETFs

SPRO


Top 10 Correlated Stocks

SPRO


In the News

06:32 03 Oct 2022 SPRO

Cheap Stocks To Buy Now? Hot Penny Stocks To Watch In October

Hot penny stocks to watch for October. The post Cheap Stocks To Buy Now?

02:30 03 Oct 2022 SPRO

Hot Penny Stocks To Watch As The Stock Market Crash Continues

Hot penny stocks to add to your watch list this week. Is it time to buy?

12:47 03 Oct 2022 SPRO

Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK

The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.

06:00 03 Oct 2022 SPRO

Reddit Penny Stocks to Watch as September Ends

Check these Reddit penny stocks out for your watchlist right now The post Reddit Penny Stocks to Watch as September Ends  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10:53 03 Oct 2022 SPRO

Spero's stock jumps 188% after GSK licenses experimental antibiotic

Shares of Spero Therapeutics Inc. SPRO, +277.39% soared 188.4% in trading on Thursday morning after the company signed an exclusive license agreement with GlaxoSmithKline GSK, -0.32% for its experimental antibiotic for complicated urinary tract infections. Spero's therapy, tebipenem HBr, is expected to enter Phase 3 clinical trials next year.

09:56 03 Oct 2022 SPRO

Spero Therapeutics (SPRO) Soars 137% on Exclusive License Agreement

Source: Willy Barton / Shutterstock.com Spero Therapeutics (NASDAQ: SPRO ) stock is rocketing higher on Thursday after the company signed a licensing agreement with GSK (NYSE: GSK ). This deal covers the rights to tebipenem HBr, which is an antibiotic asset in late-stage development by Spero Therapeutics.

06:00 03 Oct 2022 SPRO

Looking for Popular Penny Stocks to Buy? 3 to Watch Now

Which penny stocks are you buying today? The post Looking for Popular Penny Stocks to Buy?

12:02 03 Oct 2022 SPRO

Spero (SPRO) Up Following Positive FDA Update for UTI Drug

Spero (SPRO) surges on achieving common ground with the FDA on the regulatory path forward for tebipenem HBr.

10:34 03 Oct 2022 SPRO

Why Is Spero Therapeutics (SPRO) Stock Up 15% Today?

Source: Shutterstock Spero Therapeutics (NASDAQ: SPRO ) stock is climbing higher on Wednesday thanks to positive feedback from the FDA. That concerns plans to resubmit tebipenem HBr for the treatment of complicated urinary tract infection (cUTI).

08:05 03 Oct 2022 SPRO

Spero Therapeutics to Present at Upcoming Investor Conference

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the 24th Annual H.C. Wainwright Global Investment Conference, which is taking place September 12-14, 2022. Details for the presentation are as follows:

Financial details

Company Rating
Neutral
Market Cap
70.14M
Income
-113.27M
Revenue
8.77M
Book val./share
1.09
Cash/share
1.38
Dividend
-
Dividend %
-
Employees
41
Optionable
No
Shortable
Yes
Earnings
08 Nov 2022
P/E
-0.58
Forward P/E
-
PEG
6.81
P/S
7.52
P/B
1.84
P/C
1.45
P/FCF
-0.79
Quick Ratio
3.3
Current Ratio
3.65
Debt / Equity
0.15
LT Debt / Equity
0.15
-
-
EPS (TTM)
-3.49
EPS next Y
-
EPS next Q
-
EPS this Y
-17.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-30.4%
Revenue last 5Y
55.95%
Revenue Q/Q
-56.69%
EPS Q/Q
-13.86%
-
-
-
-
SMA20
104.6%
SMA50
131.17%
SMA100
-38.62%
Inst Own
61.54%
Inst Trans
-1.09%
ROA
-178%
ROE
-152%
ROC
-2.15%
Gross Margin
10%
Oper. Margin
-1212%
Profit Margin
-1291%
Payout
-
Shs Outstand
35.07M
Shs Float
24.21M
-
-
-
-
Target Price
10
52W Range
0.68-18.84
52W High
-
52W Low
-
RSI
66.96
Rel Volume
0.31
Avg Volume
7.43M
Volume
2.29M
Perf Week
143.31%
Perf Month
94.17%
Perf Quarter
-72.83%
Perf Half Y
-71.87%
-
-
-
-
Beta
1.86885
-
-
Volatility
0.08%, 0.48%
Prev Close
1.52%
Price
2
Change
2.04%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
0.770.2510.420.59
Net income per share
-14.98-2.6-3.35-3.5-2.91
Operating cash flow per share
-15.12-2.48-2.75-3.84-2.08
Free cash flow per share
-15.13-2.63-2.77-3.84-2.08
Cash per share
33.747.214.525.674.74
Book value per share
32.77.224.115.92.86
Tangible book value per share
32.847.244.115.92.86
Share holders equity per share
32.77.224.115.92.86
Interest debt per share
00000.3
Market cap
32.08M152.34M175.79M405.41M342.63M
Enterprise value
-55.21M118.26M146.06M320.2M237.38M
P/E ratio
-0.83-3.66-2.89-5.18-3.82
Price to sales ratio
16.2138.419.6943.4518.77
POCF ratio
-0.82-3.84-3.51-4.72-5.32
PFCF ratio
-0.82-3.62-3.49-4.71-5.33
P/B Ratio
0.381.322.363.073.88
PTB ratio
0.381.322.363.073.88
EV to sales
-27.929.828.0534.3213
Enterprise value over EBITDA
1.44-2.87-2.43-4.13-2.72
EV to operating cash flow
1.41-2.98-2.92-3.73-3.69
EV to free cash flow
1.41-2.81-2.9-3.72-3.69
Earnings yield
-1.21-0.27-0.35-0.19-0.26
Free cash flow yield
-1.22-0.28-0.29-0.21-0.19
Debt to equity
00000.07
Debt to assets
0.090.10.30.140.48
Net debt to EBITDA
2.270.830.491.11.21
Current ratio
11.2910.083.589.78.46
Interest coverage
0000-45.35
Income quality
1.010.950.821.10.72
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
5.483.250.862.32.28
Research and developement to revenue
16.618.543.627.183.53
Intangibles to total assets
00000
Capex to operating cash flow
00.060.0100
Capex to revenue
-0.01-0.61-0.02-0.020
Capex to depreciation
-0.07-5.96-0.42-0.210.06
Stock based compensation to revenue
0.720.690.210.520.52
Graham number
104.9820.5617.6121.5413.67
ROIC
-0.49-0.37-0.8-0.57-0.58
Return on tangible assets
-0.41-0.32-0.57-0.51-0.52
Graham Net
31.36.453.134.922.11
Working capital
83.9M111.9M68.75M124.8M139.2M
Tangible asset value
00000
Net current asset value
83.54M111.07M63.89M117.73M75.09M
Invested capital
00000.08
Average receivables
4.56M3.74M7.36M6.18M4.23M
Average payables
2.31M2.38M2.65M1.16M1.13M
Average inventory
00000
Days sales outstanding
542.8119.46171.89241.6145.59
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
0.673.062.121.518.01
Payables turnover
00000
Inventory turnover
00000
ROE
-0.46-0.36-0.82-0.59-1.02
Capex per share
-0.01-0.15-0.02-0.010

Quarterly Fundamentals Overview

Last date of statement is 2022-06-30 for Q2

Metric History 2021-06-302021-09-302021-12-312022-03-31 2022-06-30
Revenue per share
0.170.10.090.060.03
Net income per share
-0.63-0.7-0.91-1.01-0.87
Operating cash flow per share
-0.56-0.15-0.85-0.87-0.7
Free cash flow per share
-0.56-0.15-0.85-0.87-0.7
Cash per share
3.343.844.563.741.38
Book value per share
3.043.482.751.921.09
Tangible book value per share
3.043.482.751.921.09
Share holders equity per share
3.043.482.751.921.09
Interest debt per share
0.250.230.290.290.22
Market cap
414.27M591.56M514.44M283.68M24.44M
Enterprise value
350.14M485.93M409.19M218.66M-13.96M
P/E ratio
-5.58-6.57-4.4-2.16-0.21
Price to sales ratio
80.47193.07187.48137.1127.27
POCF ratio
-25.01-119.46-18.81-10.05-1.06
PFCF ratio
-25.01-119.46-18.84-10.05-1.06
P/B Ratio
4.595.295.834.540.68
PTB ratio
4.595.295.834.540.68
EV to sales
68.02158.59149.12105.69-15.58
Enterprise value over EBITDA
-19-21.72-15.09-7.250.49
EV to operating cash flow
-21.14-98.13-14.96-7.750.61
EV to free cash flow
-21.14-98.13-14.98-7.750.61
Earnings yield
-0.04-0.04-0.06-0.12-1.17
Free cash flow yield
-0.04-0.01-0.05-0.1-0.94
Debt to equity
0.070.060.070.090.15
Debt to assets
0.250.230.480.570.44
Net debt to EBITDA
3.484.723.882.161.36
Current ratio
8.297.648.461.923.65
Interest coverage
00-14.18-12.14-222.91
Income quality
0.890.220.940.860.8
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.793.644.757.48.99
Research and developement to revenue
2.814.716.288.29.12
Intangibles to total assets
00000
Capex to operating cash flow
0000-0.01
Capex to revenue
000.0100.14
Capex to depreciation
000.200.44
Stock based compensation to revenue
0.420.761.071.551.47
Graham number
6.547.417.56.594.62
ROIC
-0.17-0.18-0.18-0.39-0.53
Return on tangible assets
-0.16-0.16-0.17-0.23-0.45
Graham Net
2.412.882.031.230.57
Working capital
93.49M114.51M139.2M63.51M37.73M
Tangible asset value
00000
Net current asset value
76.97M98.97M75.09M49.35M24.25M
Invested capital
0.080.060.080.110.19
Average receivables
2.09M2.29M2.14M1.99M1.78M
Average payables
3.21M3.97M2.94M4.78M3.25M
Average inventory
00000
Days sales outstanding
38.4175.974.7886.61158.5
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
2.341.191.21.040.57
Payables turnover
00000
Inventory turnover
00000
ROE
-0.21-0.2-0.33-0.53-0.8
Capex per share
00000

Frequently Asked Questions

What is Spero Therapeutics, Inc. stock symbol ?

Spero Therapeutics, Inc. is a US stock , located in Cambridge of Massachusetts and trading under the symbol SPRO

What is Spero Therapeutics, Inc. stock quote today ?

Spero Therapeutics, Inc. stock price is $2 today.

Is Spero Therapeutics, Inc. stock public?

Yes, Spero Therapeutics, Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap